Comparison of acute versus stable coronary syndrome in patients treated with the Magmaris scaffold: Two-year results from the Magmaris Multicenter Italian Registry

Cardiovasc Revasc Med

12 September Sep 2023 10 days ago
  • Galli S, Troiano S, Ravagnani P, Montorsi P.

The magnesium Magmaris scaffold is the latest resorbable technology with low thrombogenicity, short scaffolding time, and almost complete resorption at 12 months (95 %). As compared with stable coronary artery disease (SCAD), acute coronary syndrome (ACS) is associated with increased risk of adverse clinical outcome after percutaneous coronary intervention. We analyzed the data of the Magmaris Multicenter Italian Registry to compare clinical outcomes in SCAD versus ACS patients.

Reference: Comparison of acute versus stable coronary syndrome in patients treated with the Magmaris scaffold: Two-year results from the Magmaris Multicenter Italian Registry.
Galli S, Troiano S, Palloshi A, Rapetto C, Pisano F, Aprigliano G, Leoncini M, Ravagnani P, Del Maestro M, Montorsi P. Cardiovasc Revasc Med. 2023 Jun 25:S1553-8389(23)00665-6.

Go to PubMed